Free Trial

IMAC (IMAC) Competitors

IMAC logo
$0.04 -0.01 (-12.85%)
As of 06/12/2025

IMAC vs. ACON, CANF, KZIA, EVAX, LIXT, SNPX, SONN, NUWE, APTO, and GCTK

Should you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Aclarion (ACON), Can-Fite BioPharma (CANF), Kazia Therapeutics (KZIA), Evaxion Biotech A/S (EVAX), Lixte Biotechnology (LIXT), Synaptogenix (SNPX), Sonnet BioTherapeutics (SONN), Nuwellis (NUWE), Aptose Biosciences (APTO), and GlucoTrack (GCTK). These companies are all part of the "medical" sector.

IMAC vs. Its Competitors

IMAC (NASDAQ:IMAC) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

In the previous week, IMAC and IMAC both had 2 articles in the media. Aclarion's average media sentiment score of 1.43 beat IMAC's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.

Company Overall Sentiment
IMAC Neutral
Aclarion Positive

Aclarion has a consensus target price of $11,758.50, indicating a potential upside of 157,944.35%. Given Aclarion's stronger consensus rating and higher possible upside, analysts clearly believe Aclarion is more favorable than IMAC.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IMAC
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aclarion
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Aclarion has lower revenue, but higher earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$15.22M0.07-$10.54MN/AN/A
Aclarion$54.60K79.30-$4.91MN/AN/A

IMAC received 67 more outperform votes than Aclarion when rated by MarketBeat users. Likewise, 60.17% of users gave IMAC an outperform vote while only 57.14% of users gave Aclarion an outperform vote.

CompanyUnderperformOutperform
IMACOutperform Votes
71
60.17%
Underperform Votes
47
39.83%
AclarionOutperform Votes
4
57.14%
Underperform Votes
3
42.86%

IMAC has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500.

24.3% of IMAC shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 10.0% of IMAC shares are held by insiders. Comparatively, 0.8% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

IMAC has a net margin of -75.40% compared to Aclarion's net margin of -12,845.05%. IMAC's return on equity of -52.17% beat Aclarion's return on equity.

Company Net Margins Return on Equity Return on Assets
IMAC-75.40% -52.17% -34.51%
Aclarion -12,845.05%-422.87%-201.15%

Summary

IMAC beats Aclarion on 8 of the 14 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMAC vs. The Competition

MetricIMACSpecialty Outpatient Clinics IndustryMedical SectorNASDAQ Exchange
Market Cap$1.06M$932.00K$5.58B$8.50B
Dividend YieldN/AN/A5.28%4.17%
P/E RatioN/AN/A27.1919.64
Price / Sales0.070.07408.78152.17
Price / CashN/AN/A38.3234.64
Price / Book0.060.066.974.60
Net Income-$10.54M-$10.54M$3.23B$248.06M
7 Day PerformanceN/AN/A-0.88%-1.02%
1 Month PerformanceN/AN/A7.81%3.51%
1 Year PerformanceN/AN/A31.53%12.68%

IMAC Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMAC
IMAC
N/A$0.04
-12.9%
N/A-98.5%$1.06M$15.22M0.00106Gap Down
ACON
Aclarion
2.4816 of 5 stars
$6.66
+2.8%
$11,758.50
+176,454.1%
-99.7%$3.88M$54.60K0.007Short Interest ↓
Gap Down
CANF
Can-Fite BioPharma
3.1723 of 5 stars
$1.10
+1.9%
$14.00
+1,178.5%
-65.6%$3.88M$674K-0.618Short Interest ↓
Gap Up
KZIA
Kazia Therapeutics
3.6106 of 5 stars
$3.78
-0.5%
$57.50
+1,421.2%
-21.6%$3.83M$2.31M0.0012News Coverage
Positive News
Analyst Forecast
Short Interest ↓
EVAX
Evaxion Biotech A/S
1.9875 of 5 stars
$2.72
+10.6%
$10.00
+267.6%
-82.5%$3.82M$3.29M-1.8860Short Interest ↑
Gap Up
LIXT
Lixte Biotechnology
1.0321 of 5 stars
$1.41
+20.5%
N/A-49.2%$3.78MN/A-0.824Short Interest ↓
SNPX
Synaptogenix
2.1653 of 5 stars
$2.67
+6.0%
$14.00
+424.3%
+13.0%$3.71MN/A-0.264Short Interest ↑
High Trading Volume
SONN
Sonnet BioTherapeutics
2.8225 of 5 stars
$1.17
flat
$20.00
+1,609.4%
-34.1%$3.70M$1M0.0010News Coverage
Short Interest ↓
NUWE
Nuwellis
3.0956 of 5 stars
$0.85
-1.7%
$17.00
+1,911.8%
-95.8%$3.70M$8.79M-0.0170Gap Down
APTO
Aptose Biosciences
N/AN/A$6.00
+∞
N/A$3.66MN/A-0.5831Gap Down
High Trading Volume
GCTK
GlucoTrack
1.3414 of 5 stars
$0.13
-1.9%
N/A-99.8%$3.65MN/A0.005Short Interest ↓
Gap Down

Related Companies and Tools


This page (NASDAQ:IMAC) was last updated on 6/13/2025 by MarketBeat.com Staff
From Our Partners